Next Article in Journal
Antioxidants and Cardiovascular Risk Factors
Previous Article in Journal
The Developmental Trajectory of Self-Injurious Behaviours in Individuals with Prader Willi Syndrome, Autism Spectrum Disorder and Intellectual Disability
Previous Article in Special Issue
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy
Review

Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future

1
Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore 117609, Singapore
2
Lion TCR Private Limited Singapore, Singapore 069113, Singapore
3
Emerging Infectious Diseases (EID) Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Diseases 2016, 4(1), 10; https://doi.org/10.3390/diseases4010010
Received: 16 November 2015 / Revised: 28 January 2016 / Accepted: 4 February 2016 / Published: 15 February 2016
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Cancer immunotherapy using a patient’s own T cells redirected to recognize and kill tumor cells has achieved promising results in metastatic melanoma and leukemia. This technique involves harnessing a patient’s T cells and then delivering a gene that encodes a new T cell receptor (TCR) or a chimeric antigen receptor (CAR) that allow the cells to recognize specific cancer antigens. The prospect of using engineered T cell therapy for persistent viral infections like hepatitis B virus (HBV) and their associated malignancies is promising. We recently tested in a first-in-man clinical trial, the ability of HBV-specific TCR-redirected T cells to target HBsAg-productive hepatocellular carcinoma (HCC) and demonstrated that these redirected T cells recognized HCC cells with HBV–DNA integration [1] We discuss here the possibility to use HBV-specific TCR-redirected T cells targeting hepatitis B viral antigens as a tumor specific antigen in patients with HBV-related HCC, and the potential challenges facing the development of this new immunotherapeutic strategy. View Full-Text
Keywords: immunotherapy; liver tumor; HBV; T cell engineering immunotherapy; liver tumor; HBV; T cell engineering
Show Figures

Figure 1

MDPI and ACS Style

Koh, S.; Tan, A.T.; Li, L.; Bertoletti, A. Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future. Diseases 2016, 4, 10. https://doi.org/10.3390/diseases4010010

AMA Style

Koh S, Tan AT, Li L, Bertoletti A. Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future. Diseases. 2016; 4(1):10. https://doi.org/10.3390/diseases4010010

Chicago/Turabian Style

Koh, Sarene, Anthony T. Tan, Lietao Li, and Antonio Bertoletti. 2016. "Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future" Diseases 4, no. 1: 10. https://doi.org/10.3390/diseases4010010

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop